BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fujioka M, Nakashima Y, Nakashima O, Kojiro M. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology. 2001;34:1128-1134. [PMID: 11732002 DOI: 10.1053/jhep.2001.29202] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Shim JH, Lee HC, Han S, Kang HJ, Yu E, Lee SG. Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays. Liver Transpl 2013;19:336-45. [PMID: 23203386 DOI: 10.1002/lt.23584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
2 Sumi A, Akiba J, Ogasawara S, Nakayama M, Nomura Y, Yasumoto M, Sanada S, Nakashima O, Abe T, Yano H. Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma. PLoS One 2015;10:e0118452. [PMID: 25739032 DOI: 10.1371/journal.pone.0118452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
3 Toro A, Ardiri A, Mannino M, Arcerito MC, Mannino G, Palermo F, Bertino G, Di Carlo I. Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study. BMC Surg. 2014;14:40. [PMID: 24993566 DOI: 10.1186/1471-2482-14-40] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
4 Uemura T, Kirichenko A, Bunker M, Vincent M, Machado L, Thai N. Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation. World J Surg 2019;43:886-93. [PMID: 30361748 DOI: 10.1007/s00268-018-4829-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
5 Duan Z, Gao J, Zhang L, Liang H, Huang X, Xu Q, Zhang Y, Shen T, Lu F. Phenotype and function of CXCR5+CD45RA-CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis. Oncotarget 2015;6:44239-53. [PMID: 26517519 DOI: 10.18632/oncotarget.6235] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
6 Chang Y, Cho Y, Lee JH, Lee YB, Cho EJ, Yu SJ, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers (Basel) 2019;11:E1295. [PMID: 31484287 DOI: 10.3390/cancers11091295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Zakhary NI, Khodeer SM, Shafik HE, Abdel Malak CA. Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. J Adv Res. 2013;4:539-546. [PMID: 25685463 DOI: 10.1016/j.jare.2012.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
8 Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P, Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F, Duvoux C. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552-559. [PMID: 27899297 DOI: 10.1016/j.jhep.2016.10.038] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 15.0] [Reference Citation Analysis]
9 Charrière B, Maulat C, Suc B, Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol 2016;8:881-90. [PMID: 27478538 DOI: 10.4254/wjh.v8.i21.881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
10 Asimakopoulou A, Vucur M, Luedde T, Schneiders S, Kalampoka S, Weiss TS, Weiskirchen R. Perilipin 5 and Lipocalin 2 Expression in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E385. [PMID: 30893876 DOI: 10.3390/cancers11030385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7:1632-1651. [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 18.8] [Reference Citation Analysis]
12 Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, Kagaya T, Yamashita T, Honda M, Kaneko S. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology. 2011;53:1206-1216. [PMID: 21480325 DOI: 10.1002/hep.24149] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 11.0] [Reference Citation Analysis]
13 Koya Y, Suzuki T, Tai M, Ichii O, Matsuhashi N, Ejiri Y, Miyazawa M, Shibata M, Harada M, Kumabe T, Nakashima O. Inflammatory Hepatocellular Adenoma with Elevated Serum Protein Induced by Vitamin K Absence/Antagonist-II in Adult Males. Intern Med 2019;58:1739-46. [PMID: 30799343 DOI: 10.2169/internalmedicine.1958-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Aref AM, Hoa NT, Ge L, Agrawal A, Dacosta-Iyer M, Lambrecht N, Ouyang Y, Cornforth AN, Jadus MR. HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma. Onco Targets Ther. 2014;7:1061-1070. [PMID: 24966688 DOI: 10.2147/ott.s61442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
15 Shim JH, Kang HJ, Han S, Lee Y, Lee S, Yu E, Lee HC. Prognostic value of hepatocyte nuclear factors 4α and 1α identified by tissue microarray in resectable hepatocellular carcinoma: Hepatocyte nuclear factors in liver cancer. J Gastroenterol Hepatol 2014;29:524-32. [DOI: 10.1111/jgh.12371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
16 Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129-137. [PMID: 20070666 DOI: 10.1111/j.1600-6143.2009.02750.x] [Cited by in Crossref: 175] [Cited by in F6Publishing: 146] [Article Influence: 15.9] [Reference Citation Analysis]
17 Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, Wang WT, Xu MQ, Yang JY. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol. 2013;19:1811-1819. [PMID: 23555170 DOI: 10.3748/wjg.v19.i11.1811] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
18 Yamashiki N, Gaynor JJ, Kato T, Reddy KR, Sobhonslidsuk A, Levi D, Nishida S, Madariaga J, Nery J, Schiff ER. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant. 2004;4:774-781. [PMID: 15084174 DOI: 10.1111/j.1600-6143.2004.00412.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
19 Chen XH, Zhang BH, Xin Y, Ren ZG, Fan J, Qiu SJ, Zhou J. Risk factors for residual tumor after resection of hepatocellular carcinoma. World J Gastroenterol. 2011;17:1889-1894. [PMID: 21528064 DOI: 10.3748/wjg.v17.i14.1889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Nozawa S. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:e189-e197. [PMID: 18466288 DOI: 10.1111/j.1440-1746.2008.05340.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
21 Pommergaard HC, Rostved AA, Adam R, Thygesen LC, Salizzoni M, Gómez Bravo MA, Cherqui D, Filipponi F, Boudjema K, Mazzaferro V, Soubrane O, García-Valdecasas JC, Prous JF, Pinna AD, O'Grady J, Karam V, Duvoux C, Rasmussen A; European Liver and Intestine Transplant Association (ELITA). Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. HPB (Oxford) 2018;20:768-75. [PMID: 29622402 DOI: 10.1016/j.hpb.2018.03.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
22 Refai NS, Louka ML, Halim HY, Montasser I. Long non-coding RNAs (CASC2 and TUG1) in hepatocellular carcinoma: Clinical significance. J Gene Med 2019;21:e3112. [PMID: 31301261 DOI: 10.1002/jgm.3112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
23 Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, Otao R, Horlad H, Ishiko T, Takamori H. Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma. J Surg Oncol. 2010;102:490-496. [PMID: 19937994 DOI: 10.1002/jso.21451] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
24 Chen IP, Ariizumi S, Nakano M, Yamamoto M. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol 2014;49:117-25. [PMID: 23532638 DOI: 10.1007/s00535-013-0793-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
25 Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12:1175-1181. [PMID: 16534867 DOI: 10.3748/wjg.v12.i8.1175] [Cited by in CrossRef: 190] [Cited by in F6Publishing: 171] [Article Influence: 12.7] [Reference Citation Analysis]
26 Shim JH, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Half-life of serum alpha-fetoprotein: an early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma. Ann Surg 2013;257:708-17. [PMID: 23108121 DOI: 10.1097/SLA.0b013e318273be70] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
27 Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5:795-804. [PMID: 15760404 DOI: 10.1111/j.1600-6143.2005.00750.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 116] [Article Influence: 8.8] [Reference Citation Analysis]
28 An J, Na SK, Shim JH, Park YS, Jun MJ, Lee JH, Song GW, Lee HC, Yu E. Histological expression of methionine adenosyl transferase (MAT) 2A as a post-surgical prognostic surrogate in patients with hepatocellular carcinoma. J Surg Oncol. 2018;117:892-901. [PMID: 29448301 DOI: 10.1002/jso.24994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Muscari F, Guinard JP, Kamar N, Peron JM, Otal P, Suc B. Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. World J Surg. 2012;36:1824-1831. [PMID: 22532309 DOI: 10.1007/s00268-012-1587-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
30 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
31 Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012;82:116-40. [DOI: 10.1016/j.critrevonc.2011.05.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
32 Mizukoshi E, Fushimi K, Arai K, Yamashita T, Honda M, Kaneko S. Expression of chondroitin-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma. Liver Int 2012;32:1516-26. [DOI: 10.1111/j.1478-3231.2012.02853.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
33 Yamashita S, Kato A, Akatsuka T, Sawada T, Asai T, Koyama N, Okita K. Clinical relevance of increased serum preneoplastic antigen in hepatitis C-related hepatocellular carcinoma. World J Gastroenterol 2020;26:1463-73. [PMID: 32308347 DOI: 10.3748/wjg.v26.i13.1463] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1541-1548. [PMID: 18422961 DOI: 10.1111/j.1440-1746.2008.05395.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 7.8] [Reference Citation Analysis]
35 Gelli M, Sebagh M, Porcher R, Romanelli E, Vibert E, Sa Cunha A, Castaing D, Rosmorduc O, Samuel D, Adam R, Cherqui D. Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation. Ann Surg 2020;272:820-6. [PMID: 32833755 DOI: 10.1097/SLA.0000000000004259] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer. 2006;118:1194-1204. [PMID: 16152611 DOI: 10.1002/ijc.21468] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
37 Duvoux C, Roudot–thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard P, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux G, Chazouillères O, Salame E, Hilleret M, Lebray P, Abergel A, Debette–gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology 2012;143:986-994.e3. [DOI: 10.1053/j.gastro.2012.05.052] [Cited by in Crossref: 438] [Cited by in F6Publishing: 375] [Article Influence: 48.7] [Reference Citation Analysis]
38 Pichard V, Royer PJ, Richou C, Cauchin E, Goebes K, Gaignerie A, Masliah C, Gournay J, Gregoire M, Ferry N. Detection, Isolation, and Characterization of α-fetoprotein-specific T Cell Populations and Clones Using MHC Class I Multimer Magnetic Sorting. Journal of Immunotherapy 2008;31:246-53. [DOI: 10.1097/cji.0b013e318169d55c] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Andersson O, Nikkinen H, Kanmert D, Enander K. A multiple-ligand approach to extending the dynamic range of analyte quantification in protein microarrays. Biosensors and Bioelectronics 2009;24:2458-64. [DOI: 10.1016/j.bios.2008.12.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
40 Chan SL, Mo F, Johnson P, Li L, Tang N, Loong H, Chan AW, Koh J, Chan AT, Yeo W. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30:1529-1535. [PMID: 25968302 DOI: 10.1111/jgh.13005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
41 Mohanty S, Jensen D. Tumor Markers and Molecular Biology. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 62-81. [DOI: 10.3109/9780203092880-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Wakai T, Shirai Y, Suda T, Yokoyama N, Sakata J, Cruz PV, Kawai H, Matsuda Y, Watanabe M, Aoyagi Y. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm. World J Gastroenterol. 2006;12:546-552. [PMID: 16489666 DOI: 10.3748/wjg.v12.i4.546] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
43 Görög D, Regöly-Mérei J, Paku S, Kopper L, Nagy P. Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J Gastroenterol 2005;11:5015-8. [PMID: 16124056 DOI: 10.3748/wjg.v11.i32.5015] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
44 Nakagawa S, Beppu T, Okabe H, Sakamoto K, Kuroki H, Mima K, Nitta H, Imai K, Hayashi H, Sakamoto Y. Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma. Hepatol Res. 2014;44:964-974. [PMID: 24245496 DOI: 10.1111/hepr.12277] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]